First-in-Human Safety, Tolerability, Efficacy, and Pharmacokinetics of Pegfosimer Manganese (SN132D) for Contrast-Enhanced MRI of Breast Cancer
The FIH study of pegfosimer manganese demonstrated an acceptable safety profile and sufficient contrast enhancement for clinically relevant MRI sequences in participants with primary breast tumors.
Authors
- Oskar Axelsson (ORCID: https://orcid.org/0000-0003-3209-7241)
- Dan Curiac
- P. Hargreaves (ORCID: https://orcid.org/0000-0002-3909-5225)
- Mats Hansen
- Andreas Karakatsanis (ORCID: https://orcid.org/0000-0003-3622-3575)
- Sujinna Lekmeechai (ORCID: https://orcid.org/0009-0004-5833-5644)
- Fredrik Wärnberg (ORCID: https://orcid.org/0000-0002-6274-2435)
Institutions
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Investigative Radiology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1097/rli.0000000000001164
- Citations
- 1
- Primary Topic
- MRI in cancer diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 1.36